Guardant Health
2686 Middlefield Rd, Suite C,D,E
Redwood City
California
94063
United States
173 articles with Guardant Health
-
Guardant Health Announces Pricing of Upsized Public Offering
6/1/2020
Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today announced the pricing of an underwritten public offering of 11,500,000 shares of its common stock at a public offering price of $84.00 per share,
-
Guardant Health to Participate in the William Blair 2020 Growth Stock Conference
5/29/2020
Guardant Health, Inc. (Nasdaq: GH) today announced the company will be participating in the upcoming William Blair Virtual Growth Stock Conference.
-
Guardant Health Data at ASCO and AACR Demonstrates Growing Value of Liquid Biopsy for Precision Oncology in Advanced and Early Stage Cancer
5/15/2020
Guardant Health, Inc. (Nasdaq: GH) along with leading academic institutions and pharmaceutical companies will present data highlighting the use of the company’s proprietary blood tests to advance precision oncology across the continuum of care at the upcoming 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, being held from May 29-31; and the AACR Virtual Annual Meeting II, scheduled for June 22-24.
-
Guardant Health Reports First Quarter 2020 Financial Results
5/7/2020
Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, reported financial results for the quarter ended March 31, 2020.
-
Guardant Health to Participate in the BofA Securities 2020 Healthcare Conference
5/6/2020
Guardant Health, Inc. announced the company will be participating in the upcoming BofA Securities Virtual Healthcare Conference.
-
Guardant Health and Patient Advocacy Groups Join Forces to Raise Awareness of the Importance of Complete Biomarker Testing for Patients with Metastatic Non-Small Cell Lung Cancer
5/5/2020
Incomplete testing fails to meet current medical guideline standards, placing more than 80 percent1 of patients at increased risk of receiving a less effective treatment
-
Guardant Health Presents Data at DDW Virtual Meeting Highlighting its Early Cancer Detection ProgramStudies feature the LUNAR-2 liquid biopsy and its potential to improve colorectal cancer screening rates
5/2/2020
Guardant Health, Inc. presents new data at Digestive Disease Week 2020 that highlights the performance of its LUNAR-2 assay and reinforces its potential to improve colorectal cancer screening rates by offering a simpler blood test that overcomes barriers associated with current testing methods.
-
Guardant Health Announces Webcast of First Quarter Financial Results on May 7, 2020
4/30/2020
Guardant Health, Inc. announced it will report financial results for the first quarter 2020 after market close on Thursday, May 7, 2020.
-
Clinical Catch-Up: April 13-17
4/20/2020
There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look. -
Study Shows Guardant360 Test Identifies Predictors of Response to PIK3CA Inhibitors in Women with HR+ Metastatic Breast Cancer
4/9/2020
Many women with metastatic hormone receptor-positive breast cancer have experienced improved clinical outcomes with the recent introduction of alpelisib, a PIK3CA inhibitor.
-
Guardant Health Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Full Year 2020 OutlookFull Year 2019 Revenue Increase of 137% Over 2018
2/24/2020
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the fourth quarter and full year ended December 31, 2019.
-
Guardant Health to Participate in Upcoming Investor Conferences - Feb. 12, 2020
2/12/2020
Guardant Health, Inc. announced the company will be participating in two upcoming investor conferences.
-
Guardant Health to Report Fourth Quarter and Full Year 2019 Financial Results on February 24, 2020
2/10/2020
Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the fourth quarter and full year 2019 after market close on Monday, February 24, 2020.
-
BioSpace Movers & Shakers, Jan. 24
1/24/2020
Pharma and life sciences companies strengthen their leadership and boards with this week's appointments. -
Guardant Health Appoints High-Tech-Veteran Kumud Kalia Chief Information Officer
1/21/2020
Guardant Health, Inc. (Nasdaq: GH) a leading precision oncology company, has appointed Kumud Kalia as the company’s new Chief Information Officer (CIO).
-
Clinical Catch-Up: January 13-17
1/20/2020
There were plenty of clinical trial announcements this week. Here's a look. -
With the J.P. Morgan Healthcare Conference in full swing, companies did not waste time in announcing deals and providing updates to their pipelines. BioSpace takes a look at some of the announcements made on day one of the annual conference in the Bay Area.
-
Amgen Announces Global Diagnostic Collaborations To Expand Molecular Testing For Patients With Non-Small Cell Lung Cancer
1/13/2020
First Company Developing a KRAS(G12C) Inhibitor to Announce Multi-Platform Companion Diagnostics
-
Guardant Health Announces Collaboration With Amgen to Develop a Global Liquid Biopsy Companion Diagnostic for AMG 510 KRAS G12C Inhibitor
1/13/2020
Guardant Health, Inc., announces a strategic collaboration to develop and help support commercialization of a blood-based companion diagnostic test for Amgen’s AMG 510, an investigational oral therapy that inhibits KRAS G12C mutant protein, globally.
-
Guardant Health and NRG Oncology Initiate Randomized Trial to Investigate Circulating Tumor DNA Guided Adjuvant Therapy in Stage II Colon Cancer
1/13/2020
LUNAR-1 liquid biopsy assay will be used to identify molecular residual disease and support its validation as a diagnostic biomarker